Cytodyn Inc

CYDY:OTCQB
RT Quote | Exchange | USD
Last | 3:59 PM EST
4.81quote price arrow down-0.19 (-3.90%)
Volume
2,463,056
52 week range
0.79 - 10.01

...

Loading . . .

KEY STATS

  • Open4.99
  • Day High5.00
  • Day Low4.75
  • Prev Close5.01
  • 52 Week High10.01
  • 52 Week High Date06/30/20
  • 52 Week Low0.79
  • 52 Week Low Date02/10/20
  • Market Cap2,877.01M
  • Shares Out598.13M
  • 10 Day Average Volume0.00M
  • Dividend-
  • Dividend Yield-
  • Beta-0.45
  • 1 Year % Change343.32

RATIOS/PROFITABILITY

  • EPS (TTM)-0.31
  • P/E (TTM)-15.33
  • Fwd P/E (NTM)240.50
  • EBITDA (MRQ)-98.04M
  • ROE (MRQ)-566.11%
  • Revenue (MRQ)0.00M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-775.57%

EVENTS

  • Earnings Date04/09/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest Cytodyn Inc News

There is no recent news for this security.

Latest CYDY News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company's lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells. The Company's product pipeline also includes Cytolin and CytoFeline. Cytolin is a mouse...
Scott Kelly M.D.
Chairman
Nader Pourhassan Ph.D.
President
Michael Mulholland
Chief Financial Officer
Nitya Ray Ph.D.
Chief Technology Officer
Maura Fleming
Vice President
Address
1111 Main St Ste 660
Vancouver, WA
98660-2970
United States